Novel Agents in Heavily Pretreated Metastatic Gastric Cancer

More Shadows Than Lights

Giandomenico Roviello, Alberto D'Angelo, Raheleh Roudi, Roberto Petrioli, Enrico Mini

Research output: Contribution to journalReview article

Abstract

Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.

Original languageEnglish
Article number5692317
Number of pages9
JournalJournal of oncology
Volume2019
DOIs
Publication statusPublished - 4 Jul 2019

Cite this

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer : More Shadows Than Lights. / Roviello, Giandomenico; D'Angelo, Alberto; Roudi, Raheleh; Petrioli, Roberto; Mini, Enrico.

In: Journal of oncology, Vol. 2019, 5692317, 04.07.2019.

Research output: Contribution to journalReview article

Roviello, Giandomenico ; D'Angelo, Alberto ; Roudi, Raheleh ; Petrioli, Roberto ; Mini, Enrico. / Novel Agents in Heavily Pretreated Metastatic Gastric Cancer : More Shadows Than Lights. In: Journal of oncology. 2019 ; Vol. 2019.
@article{40e3e2a04d8e4b5e8407c6093ee163ce,
title = "Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights",
abstract = "Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.",
author = "Giandomenico Roviello and Alberto D'Angelo and Raheleh Roudi and Roberto Petrioli and Enrico Mini",
year = "2019",
month = "7",
day = "4",
doi = "10.1155/2019/5692317",
language = "English",
volume = "2019",
journal = "Journal of oncology",
issn = "1687-8450",
publisher = "Hindawi",

}

TY - JOUR

T1 - Novel Agents in Heavily Pretreated Metastatic Gastric Cancer

T2 - More Shadows Than Lights

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Roudi, Raheleh

AU - Petrioli, Roberto

AU - Mini, Enrico

PY - 2019/7/4

Y1 - 2019/7/4

N2 - Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.

AB - Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.

U2 - 10.1155/2019/5692317

DO - 10.1155/2019/5692317

M3 - Review article

VL - 2019

JO - Journal of oncology

JF - Journal of oncology

SN - 1687-8450

M1 - 5692317

ER -